The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato ... patients treated with Spravato should receive a dose twice a week for the first four ...
Medpage Today on MSN2mon
FDA Expands Approval of Esketamine for DepressionThe FDA approved esketamine (Spravato) nasal spray as monotherapy ... with least-square mean differences of -5.1 with the ...
although more than one dose may be used depending on a patient's age and other factors. Spravato is approved as an adjunctive therapy administered by a nasal spray and is based on esketamine ...
In some patients, there was a measurable shift on the MADRS scale within around 24 hours of the first dose, according to J&J. That speed of onset has been held up as the main benefit for Spravato ...
Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...
Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback